SFM
DMRA

Sphera Funds Management’s Damora Therapeutics DMRA Stock Holding History

Sphera Funds Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,921
Closed -$2.72M – 148
2021
Q1 		$2.72M Buy
17,921
+2,250
+14% +$612K 0.21% 97
2020
Q4 		$4.67M Buy
+15,671
New +$5.83M 0.41% 70

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Sphera Funds Management's DMRA Position: Q2 2021 in Review

Sphera Funds Management sold out of Damora Therapeutics (DMRA) in Q2 2021, closing a stake of 17,921 shares — an estimated $2.72M sold.

Sphera Funds Management first reported a position in DMRA in Q4 2020 and held it in 2 quarters. The position peaked at $4.67M in Q4 2020. 26 funds tracked by Wall St. Rank hold DMRA as of Q2 2021.

  • Sphera Funds Management reported no remaining Damora Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sphera Funds Management sold 17,921 Damora Therapeutics shares in Q2 2021, an estimated $2.72M.
  • Sphera Funds Management first reported a position in Damora Therapeutics in Q4 2020 and held it in 2 quarters.
  • Sphera Funds Management's Damora Therapeutics position peaked at $4.67M in Q4 2020.
  • 26 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2021.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.